Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-14 labeled BI 1015550 metabolism and pharmacokinetics study in healthy males
NCT04771286Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nerandomilast, sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of the Amount of [14C]-Radioactivity Excreted Among the Administered Single Oral Dose. Started Mar 2021; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT04771286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771286.